Ir a las transacciones
Salud

Shield Therapeutics has completed a fundraising

Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.

Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.

Contáctese con el equipo de la transacción

 Geoff  Nash

Geoff Nash

Director
Londres, Reino Unido
Oaklins Cavendish

Transacciones relacionadas

Xeros Technology Group has completed a placing, subscription and retail offer
Maquinaria y Componentes Industriales

Xeros Technology Group has completed a placing, subscription and retail offer

Xeros Technology Group plc has raised funds to drive forward its commercialization strategy.

Aprenda más
PCI Pal has completed an equity raise
Servicios Financieros | TMT

PCI Pal has completed an equity raise

PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.

Aprenda más
CARSO Group has acquired a majority stake in AQCF Group
Private Equity | Servicios de Soporte Comercial | Salud

CARSO Group has acquired a majority stake in AQCF Group

CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.

Aprenda más